Maynard Um
-
-
-
-
-
-
-
MoonLake Immunotherapeutics (MLTX) Misses Q1 EPS by 9c
-
-
-
-
-
-
-
Moonlake Immunotherapeutics (MLTX) Reiterated at Overweight by Cantor Fitzgerald
-
-
-
-
-
-
-
MoonLake receives FDA guidance for drug approval without new trials
-
-
-
-
-
-
-
Goldman Sachs Downgrades Moonlake Immunotherapeutics (MLTX) to Neutral
-
-
-
-
-
-
-
BTIG Downgrades Moonlake Immunotherapeutics (MLTX) to Neutral
-
-
-
-
-
-
-
Clear Street Reiterates Buy Rating on Moonlake Immunotherapeutics (MLTX)
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Moonlake Immunotherapeutics (MLTX)
-
417,308 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

